Anal Cancer, Colon Cancer, Colorectal Cancer , Pancreatic Cancer , Rectal Cancer
Dr. Sahin received his MD degree from Hacettepe University School of Medicine in Ankara, Turkey. He completed 2 years of postdoctoral fellowship in Gastrointestinal Oncology Department/Experimental Therapeutics Department at MD Anderson Cancer Center. He completed an Internal Medicine Residency at Icahn School of Medicine at Mount Sinai followed by a Hematology/Oncology Fellowship at Emory University School of Medicine. Dr. Sahin received ASCO Conquer Cancer Merit Award and Rochfort scholarship during his Hematology/Oncology fellowship training. He was also selected to participate prestigious AACR/ASCO Methods in Clinical Research Workshop in 2019. Dr. Sahin’s clinical and research interests focus on colorectal and pancreatic cancer and designing clinical trials with immunotherapy and targeted therapy.
Education & Training
Emory University School of Medicine - Hematology/Oncology
UT MD Anderson Cancer Center -
Icahn School of Medicine at Mount Sinai St Luke's Roosevelt Hospital - Internal Medicine
Bigness A, Imanirad I, Sahin IH, Xie H, Frakes J, Hoffe S, Laskowitz D, Felder S. Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation. CA-Cancer J Clin. 2021 May.71(3):198-208. Pubmedid: 33592118.
Sahin IH, Klostergaard J. BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues. JCO Oncol Pract. 2021 Jun.OP2100160. Pubmedid: 34077235.
Sahin IH, Khalil L, Millett R, Kaseb A. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook. Chin Clin Oncol. 2021 Feb.10(1):7. Pubmedid: 33440948.
Tan E, Sahin IH. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches. Expert Rev Gastroenterol Hepatol. 2021 Feb.1-8. Pubmedid: 33539189.
Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, Bekaii-Saab T, Lesinski GB, El-Rayes BF, Wu C. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist. 2021 Feb. Pubmedid: 33631043.
Naffouje S, Sabesan A, Powers BD, Dessureault S, Sanchez J, Schell M, Imanirad I, Sahin I, Xie H, Felder S. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision. Clin Colorectal Cancer. 2021 Feb. Pubmedid: 33775560.
Sahin IH, Tan E, Kim R. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opin Inv Drug. 2021 Apr.30(4):333-341. Pubmedid: 33378249.
Askan G, Sahin IH, Chou JF, Yavas A, Capanu M, Iacobuzio-Donahue CA, Basturk O, O'Reilly EM. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. BMC Cancer. 2021 Apr.21(1):385. Pubmedid: 33836674. Pmcid: PMC8034174.
Sahin IH. Precision medicine for gastrointestinal cancers: a conference report. Future Sci OA. 2020 May.6(6):FSO478. Pubmedid: 32670606. Pmcid: PMC7351088.
Sahin IH, Kane SR, Brutcher E, Guadagno J, Smith KE, Wu C, Lesinski GB, Gunthel CJ, El-Rayes BF. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. JCO Oncol Pract. 2020 Jun.16(6):319-325. Pubmedid: 32160138.
Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist. 2020 Aug.25(8):669-679. Pubmedid: 31943525. Pmcid: PMC7418359.
Guler I, Askan G, Klostergaard J, Sahin IH. Precision medicine for metastatic colorectal cancer: an evolving era. Expert Rev Gastroenterol Hepatol. 2019 Oct.13(10):919-931. Pubmedid: 31475851.
Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Brit J Cancer. 2019 Nov.121(10):809-818. Pubmedid: 31607751. Pmcid: PMC6889302.
Uzunparmak B, Sahin IH. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med. 2019 Jan.8(1):2. Pubmedid: 30645701. Pmcid: PMC6333596.
Uzunparmak B, Sahin IH. Comment on "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer". Brit J Cancer. 2018 Oct.119(7):908. Pubmedid: 30297772. Pmcid: PMC6189067.
Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res. 2018 Mar.24(6):1326-1336. Pubmedid: 29367431. Pmcid: PMC5856632.
Sahin IH, Elias H, Chou JF, Capanu M, O'Reilly EM. Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. BMC Cancer. 2018 Jul.18(1):769. Pubmedid: 30055578. Pmcid: PMC6064173.
Sahin IH, Elias H. Molecular Profiling of Pancreatic Cancer Patients-Letter. Clin Cancer Res. 2018 Dec.24(24):6611. Pubmedid: 30552236.
Sahin IH, Askan G, Hu ZI, O'Reilly EM. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. Ann Oncol. 2017 Dec.28(12):2950-2961. Pubmedid: 28945842. Pmcid: PMC5834032.
Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016 Sep.20(3):341-359. Pubmedid: 26439702. Pmcid: PMC4985526.
Sahin IH, Klostergaard J. CD44 as a drug delivery target in human cancers: where are we now?. Expert Opin Ther Targets. 2016 Sep.19(12):1587-1591. Pubmedid: 26374284.
Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol. 2016 Oct.7(5):340-351. Pubmedid: 27777877. Pmcid: PMC5056326.
Sahin IH, Geyer AI, Kelly DW, O'Reilly EM. Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. Clin Colorectal Cancer. 2016 Mar.15(1):24-31. Pubmedid: 26395520. Pmcid: PMC4981480.
Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Rev Gastroenterol Hepatol. 2016 Aug.10(8):893-905. Pubmedid: 26881472. Pmcid: PMC4988832.
Sahin IH, Uzunparmak B. Comment on: α-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Brit J Cancer. 2015 May.112(11):1838. Pubmedid: 25602961. Pmcid: PMC4647247.
Tanasanvimon S, Garg N, Viswanathan C, Truong M, Kaur H, Kee BK, Sahin IH, Javle MM, Garrett CR. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res. 2014 Feb.133(2):154-157. Pubmedid: 24331209.
Sahin IH, Hassan MM, Garrett CR. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science. Cancer Lett. 2014 Apr.345(2):249-257. Pubmedid: 24021750.
Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology-Basel. 2013 Nov.85(4):197-203. Pubmedid: 24051705. Pmcid: PMC3913463.
Sahin IH, Oktay AA. EGFR signalling and oncogenic pathway signature in colorectal cancer. Gut. 2013 Nov.62(11):1670. Pubmedid: 23532175.
Sahin IH. The impact of aspirin use on colorectal cancer patients. Eur J Cancer. 2013 Jun.49(9):2274-2275. Pubmedid: 23541569.
Sahin IH, Garrett C. Aspirin, PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2013 Jan.368(3):289. Pubmedid: 23323915.
Sahin HI, Kaseb A. A comment on 'A morpho-molecular prognostic model for hepatocellular carcinoma'. Brit J Cancer. 2013 Feb.108(3):740. Pubmedid: 23422789. Pmcid: PMC3593531.
Oktay AA, Alpay SN, Sahin IH. Re: Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 Dec.105(23):1837. Pubmedid: 24168969.
Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. J Cancer. 2013 Apr.4(4):320-322. Pubmedid: 23569465. Pmcid: PMC3619093.
Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN, Ozpolat B. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012 Jul.7(7):e41171. Pubmedid: 22911754. Pmcid: PMC3401164.
Sahin IH, Shama MA, Tanaka M, Abbruzzese JL, Curley SA, Hassan M, Li D. Association of diabetes and perineural invasion in pancreatic cancer. Cancer Med. 2012 Dec.1(3):357-362. Pubmedid: 23342285. Pmcid: PMC3544459.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub